z-logo
open-access-imgOpen Access
Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review
Author(s) -
Zhang Jeff F,
Piryani Ravi,
Swayampakula Anil K,
Farooq Osman
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5586
Subject(s) - levetiracetam , dosing , medicine , aggression , anxiety , anesthesia , adverse effect , piracetam , sedation , depression (economics) , antiepileptic drug , pediatrics , psychiatry , epilepsy , economics , macroeconomics
Levetiracetam is a second‐generation antiepileptic medication used to treat a wide range of partial and generalized seizure disorders. While Levetiracetam is generally well‐tolerated, mild mood‐related side effects (e.g., anxiety, agitation, and depression) have been observed in a minority of patients in the days following initiation of therapy or changes in dosing. The development of acute aggression requiring termination of Levetiracetam therapy has been rarely reported in the medical literature but poses a limiting effect on treatment options for refractory epilepsy in pediatric patients. In this report, we present a teenage male patient with a history of seizure disorder who developed sudden, severe behavioral abnormalities and aggression following increases in his Levetiracetam dosing. His symptoms resolved rapidly after return of his medication dosing to baseline, with no further sequelae noted. Our observations suggest that Levetiracetam remains a safe and effective first‐line antiepileptic whose adverse behavioral side effect profile can be properly managed with close patient monitoring and dose titration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here